Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
POSTED
09-22-14
Calling for a life-course approach in post-2015 development agenda
Non-communicable diseases (NCDs) are not just a health issue, but a critical and cross cutting development issue that threatens social and economic progress in many parts of the world. The post-2015 development agenda is an opportunity to steer a healthier course for both current and future g...
POSTED
09-19-14
Novo Nordisk advocates for health on the post-2015 development agenda
Eight million people below the age of 60 die each year in low- and middle- income countries from preventable causes, including unhealthy diets, alcohol consumption and physical inactivity leading to non-communicable diseases (NCDs).[1]
POSTED
06-23-14
Mandatory CSR in India Means Business as Usual for Novo Nordisk
For two decades, Novo Nordisk has been working to support the Indian healthcare infrastructure to cope with the millions of people living with diabetes. Going beyond philanthropy, the company has taken a holistic approach to diabetes care, raising awareness of diabetes, building healthcare pr...
POSTED
06-11-14
Measuring the Value of Partnerships to Change Diabetes in India
Today, Novo Nordisk published its sixth business case demonstrating the shared value the company creates through its business activities. The latest Blueprint for Change case study, Developing partnerships to change diabetes in India, s...
POSTED
05-28-14
Green Solutions Can Reverse Rise in Chronic Diseases
Today, Novo Nordisk and sustainability think tank Sustainia present a new approach in the fight against chronic diseases based on green innovations. Accounting for more than 63 percent of all global deaths[1], chronic diseases have become an alarming issue that the healthcare sector cannot handle...
POSTED
05-19-14
Novo Nordisk Wins Two Awards for its 2012 Reporting
Bringing its total to eight first place awards, Novo Nordisk was honoured for having the Best Integrated Report and for demonstrating Credibility Through Assurance for the company’s 2012 Annual Report. The awards were announced at the Corporate Register Reporting Awards (CRRA) in London on 15 May...
POSTED
04-10-14
Clinics Bring Life-changing Care to Ghana's Capital
Two new clinics were created as part of Novo Nordisk's Base of the Pyramid programme, which is creating partnerships to build sustainable access to diabetes ...
POSTED
04-08-14
New Model Needed in Diabetes Care
Participants at the 5th International DAWN™ Summit (Diabetes Attitudes Wishes and Needs) today pledged to work together to make person-centred diabetes care a reality for the 382 million people living with diabetes around the world.[i]
While it is widely ack...
POSTED
03-28-14
Novo Nordisk Launches 'Cities Changing Diabetes' to Fight Urban Diabetes
Novo Nordisk today announces the launch of ‘Cities Changing Diabetes’, an ambitious new partnership programme to fight the urban diabetes challenge. The ‘Cities Changing Diabetes’ programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow.
POSTED
02-27-14
The Story of Novo Nordisk's Environmental Profit and Loss Account
Novo Nordisk has become the first pharmaceutical company in the world to publish an Environmental Profit and Loss (E P&L) account. The story behind the E P&L is told in the latest issue of Novo Nordisk’s sustainability magazine –